Please login to the form below

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

Novartis eyes potential new indication for Cosentyx

This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

Latest news

J&J's Tremfya filed for approval in US for psoriatic arthritis

This includes Novartis’ Consentyx (secukinumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate) , which are all already approved in psoriatic arthritis.
AbbVie scores FDA approval for arthritis treatment upadacitinib

The JAK inhibitor market competition has also become increasingly saturated and upadacitinib will be taking on Pfizer’s Xeljanz and Eli Lilly’s Olumiant when it comes to market. ... However, there have been some safety concerns regarding the class,
Gilead strikes $5.1bn deal to bolster ties with Galapagos

Filgotinib is however up against some tough competition in the market, from Pfizer’s blockbuster Xeljanz (tofacitinib) – already approved for RA, psoriatic arthritis and ulcerative colitis – as well as AbbVie’s
GSK pushes rheumatoid arthritis antibody into phase 3

antibody Kevzara (sarilumab) and Pfizer’s JAK inhibitor Xeljanz (tofacitinib), to try to differentiate its drug.
Tremfya heads for filing in psoriatic arthritis

Cosentyx. While Stelara remains in a solid second place behind runaway leader Humira, Cosentyx, AbbVie’s Skyrizi, Eli Lilly’s Taltz and Pfizer's Xeljanz also already approved in psoriatic arthritis.

More from news
Approximately 18 fully matching, plus 52 partially matching documents found.

Latest Intelligence

Pharma deals during September 2013

antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Brand leaders in RA will lose market share, predict rheumatologists

JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. . ... The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Events Executive: DOE

Account Director – UK Office: Excellent salary and benefits

Client Services Director- Flexible Working: Negotiable

Account Manager – Healthcare advertising: Salary TBC

Senior Medical Writer: Competitive salary plus benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...